

## Special Issue

# Combating Tumor Radioresistance

### Message from the Guest Editors

Radiotherapy (RT) is a modality of oncologic treatment that can be used to treat approximately 50% of all cancer patients either alone or in combination with other treatments. Despite the technological advances in RT, which allow a more precise delivery of radiation while progressively minimizing the impact on normal tissues, radioresistance and tumor recurrence remain important challenges. More research is also needed regarding the great potential of particle therapy in radioresistant cancers. Moreover, the identification of targetable pathways in combination with radiation is also of great interest in this issue. This special issue will include reports of pre-clinical data on all aspects modulating radioresistance of tumor cells in experimental systems in vitro and in vivo, including combinations of ionizing radiation with novel substances, e. g. immunotherapy, targeted therapy or chemotherapy. In addition, reports on prospective and retrospective clinical trials and case series focusing on tumor control and tumor radioresistance will be central to the special issue. Clinical contributions will include all advanced methods of photon and particle radiotherapy.

### Guest Editors

Prof. Dr. Dirk Vordermark

Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, 06120 Halle (Saale), Germany

Prof. Dr. María Isabel Núñez

Department of Radiology and Physical Medicine, Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research University of Granada, 18016 Granada, Spain

### Deadline for manuscript submissions

closed (20 May 2023)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/109347](https://mdpi.com/si/109347)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)